TAO Synergies (TAOX) Retained Earnings (2020 - 2026)
TAO Synergies' (TAOX) quarterly Retained Earnings came in at $94.4 million in Q2 2026, up 15.46% on a YoY basis from $81.7 million in Q2 2025, and down 1.06% quarter-over-quarter from $95.4 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Retained Earnings (2020 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Retained Earnings for 7 consecutive years, with $94.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Retained Earnings rose 15.46% year-over-year to $94.4 million; the trailing twelve-month figure through Jun 2026 stood at $94.4 million (up 15.46% YoY), and the FY2025 full-year result was $97.2 million, up 83.38% from the prior year.
- Retained Earnings eased to $94.4 million in Q2 2026 per TAOX's latest filing, from $95.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $97.2 million in Q4 2025 and bottomed at $49.1 million in Q1 2022.
- Historically, Retained Earnings has averaged $64.0 million across 5 years, with a median of $55.2 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings soared 144.38% in 2022, then decreased 8.51% in 2024.
- Over 5 years, Retained Earnings stood at $52.5 million in 2022, then rose by 10.34% to $58.0 million in 2023, then declined by 8.51% to $53.0 million in 2024, then surged by 83.38% to $97.2 million in 2025, then slipped by 2.93% to $94.4 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $94.4 million, $95.4 million, and $97.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.98 Bn | 196.99 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 181.24 Bn | 178.06 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 132.38 Bn | 124.53 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 82.97 Bn | 74.97 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 54.80 Bn | 49.67 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 34.09 Bn | 30.78 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.34 Bn | 30.05 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn | 5.13 Bn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | 94.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 94.39 Mn |
| Mar 31, 2026 | 95.40 Mn |
| Dec 31, 2025 | 97.24 Mn |
| Sep 30, 2025 | 84.53 Mn |
| Jun 30, 2025 | 81.75 Mn |
| Mar 31, 2025 | 52.05 Mn |
| Dec 31, 2024 | 53.03 Mn |
| Sep 30, 2024 | 54.31 Mn |
| Jun 30, 2024 | 54.26 Mn |
| Mar 31, 2024 | 56.09 Mn |
| Dec 31, 2023 | 57.96 Mn |
| Sep 30, 2023 | 59.12 Mn |
| Jun 30, 2023 | 56.85 Mn |
| Mar 31, 2023 | 53.27 Mn |
| Dec 31, 2022 | 52.52 Mn |
| Sep 30, 2022 | 50.86 Mn |
| Jun 30, 2022 | 50.12 Mn |
| Mar 31, 2022 | 49.10 Mn |
| Dec 31, 2021 | 47.67 Mn |
| Sep 30, 2021 | 41.26 Mn |